Serum levels of vault RNA significantly varied in patients with haematological malignancies

Kato,Haruka; Hashimoto,Yuki; Hatayama,Yuki; Shimohiro,Hisashi; Motokura,Toru

doi:10.3892/mmr.2023.13077

Serum levels of vault RNA significantly varied in patients with haematological malignancies

Authors:
- Haruka Kato
- Yuki Hashimoto
- Yuki Hatayama
- Hisashi Shimohiro
- Toru Motokura
View Affiliations

Affiliations: Department of Pathobiological Science and Technology, School of Health Science, Tottori University Faculty of Medicine, Yonago, Tottori 683‑8503, Japan, Division of Clinical Laboratory, Tottori University Hospital, Yonago, Tottori 683‑8504, Japan, Division of Clinical Laboratory Medicine, Department of Multidisciplinary Internal Medicine, Tottori University Faculty of Medicine, Yonago, Tottori 683‑8503, Japan
Published online on: August 28, 2023 https://doi.org/10.3892/mmr.2023.13077
Article Number: 190

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Among extracellular non‑coding RNAs, serum levels of microRNAs have been extensively investigated in cancers. In contrast, the serum levels of vault RNAs (vtRNAs) in relation to various disease conditions remain poorly understood. The present study evaluated the clinical significance of serum vtRNA1‑1 levels in patients with blood diseases. The stability and sub‑localisation of serum vtRNA1‑1 was assessed and a reverse transcription‑quantitative PCR method using spiked RNA to quantify serum vtRNA1‑1 was developed. Serum vtRNA1‑1 levels were assessed in 102 individuals with blood diseases. Serum vtRNA1‑1 was demonstrated to be stable for three weeks at 4˚C and was not confined to the exosome fractions. Spiking RNA was used to correct for the inconsistency in RNA extraction. The serum vtRNA1‑1 levels ranged between 7.28 and 8.76 log10 cps/ml (median 8.05) in control individuals (n=46). Serum vtRNA1‑1 levels correlated with leukocyte counts and increased to a maximum of 10.01 log10 cps/ml in patients with bulky leukaemia and lymphoma and decreased to 6.52 log10 cps/ml during intensive chemotherapy. The serum vtRNA1‑1 levels varied significantly in patients with haematological malignancies. Serum vtRNA1‑1 may originate from haematological cells and are a potential biomarker of normal and malignant haematological activities.

View References

1	Kedersha NL and Rome LH: Isolation and characterization of a novel ribonucleoprotein particle: Large structures contain a single species of small RNA. J Cell Biol. 103:699–709. 1986. View Article : Google Scholar : PubMed/NCBI
2	Stadler PF, Chen JJ, Hackermüller J, Hoffmann S, Horn F, Khaitovich P, Kretzschmar AK, Mosig A, Prohaska SJ, Qi X, et al: Evolution of vault RNAs. Mol Biol Evol. 26:1975–1991. 2009. View Article : Google Scholar : PubMed/NCBI
3	Kickhoefer VA, Searles RP, Kedersha NL, Garber ME, Johnson DL and Rome LH: Vault ribonucleoprotein particles from rat and bullfrog contain a related small RNA that is transcribed by RNA polymerase III. J Biol Chem. 268:7868–7873. 1993. View Article : Google Scholar : PubMed/NCBI
4	Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M, et al: A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 129:1401–1414. 2007. View Article : Google Scholar : PubMed/NCBI
5	Lee K, Kunkeaw N, Jeon SH, Lee I, Johnson BH, Kang GY, Bang JY, Park HS, Leelayuwat C and Lee YS: Precursor miR-886, a novel noncoding RNA repressed in cancer, associates with PKR and modulates its activity. RNA. 17:1076–1089. 2011. View Article : Google Scholar : PubMed/NCBI
6	Nandy C, Mrázek J, Stoiber H, Grässer FA, Hüttenhofer A and Polacek N: Epstein-Barr virus-induced expression of a novel human vault RNA. J Mol Biol. 388:776–784. 2009. View Article : Google Scholar : PubMed/NCBI
7	Li F, Chen Y, Zhang Z, Ouyang J, Wang Y, Yan R, Huang S, Gao GF, Guo G and Chen JL: Robust expression of vault RNAs induced by influenza A virus plays a critical role in suppression of PKR-mediated innate immunity. Nucleic Acids Res. 43:10321–10337. 2015.PubMed/NCBI
8	Amort M, Nachbauer B, Tuzlak S, Kieser A, Schepers A, Villunger A and Polacek N: Expression of the vault RNA protects cells from undergoing apoptosis. Nat Commun. 6:70302015. View Article : Google Scholar : PubMed/NCBI
9	Gopinath SC, Wadhwa R and Kumar PK: Expression of noncoding vault RNA in human malignant cells and its importance in mitoxantrone resistance. Mol Cancer Res. 8:1536–1546. 2010. View Article : Google Scholar : PubMed/NCBI
10	Chen J, OuYang H, An X and Liu S: Vault RNAs partially induces drug resistance of human tumor cells MCF-7 by binding to the RNA/DNA-binding protein PSF and inducing oncogene GAGE6. PLoS One. 13:e01913252018. View Article : Google Scholar : PubMed/NCBI
11	Bracher L, Ferro I, Pulido-Quetglas C, Ruepp MD, Johnson R and Polacek N: Human vtRNA1-1 levels modulate signaling pathways and regulate apoptosis in human cancer cells. Biomolecules. 10:6142020. View Article : Google Scholar : PubMed/NCBI
12	Ferro I, Gavini J, Gallo S, Bracher L, Landolfo M, Candinas D, Stroka DM and Polacek N: The human vault RNA enhances tumorigenesis and chemoresistance through the lysosome in hepatocellular carcinoma. Autophagy. 18:191–203. 2022. View Article : Google Scholar : PubMed/NCBI
13	Horos R, Buscher M, Kleinendorst R, Alleaume AM, Tarafder AK, Schwarzl T, Dziuba D, Tischer C, Zielonka EM, Adak A, et al: The small non-coding vault RNA1-1 acts as a riboregulator of autophagy. Cell. 176:1054–1067. e122019. View Article : Google Scholar : PubMed/NCBI
14	Buscher M, Horos R, Huppertz I, Haubrich K, Dobrev N, Baudin F, Hennig J and Hentze MW: Vault RNA1-1 riboregulates the autophagic function of p62 by binding to lysine 7 and arginine 21, both of which are critical for p62 oligomerization. RNA. 28:742–755. 2022. View Article : Google Scholar : PubMed/NCBI
15	Gallo S, Kong E, Ferro I and Polacek N: Small but powerful: The human vault RNAs as multifaceted modulators of pro-survival characteristics and tumorigenesis. Cancers (Basel). 14:27872022. View Article : Google Scholar : PubMed/NCBI
16	Nolte-'t Hoen EN, Buermans HP, Waasdorp M, Stoorvogel W, Wauben MH and 't Hoen PA: Deep sequencing of RNA from immune cell-derived vesicles uncovers the selective incorporation of small non-coding RNA biotypes with potential regulatory functions. Nucleic Acids Res. 40:9272–9285. 2012. View Article : Google Scholar : PubMed/NCBI
17	Shurtleff MJ, Yao J, Qin Y, Nottingham RM, Temoche-Diaz MM, Schekman R and Lambowitz AM: Broad role for YBX1 in defining the small noncoding RNA composition of exosomes. Proc Natl Acad Sci USA. 114:E8987–E8995. 2017. View Article : Google Scholar : PubMed/NCBI
18	Ramayanti O, Verkuijlen SAWM, Novianti P, Scheepbouwer C, Misovic B, Koppers-Lalic D, van Weering J, Beckers L, Adham M, Martorelli D, et al: Vesicle-bound EBV-BART13-3p miRNA in circulation distinguishes nasopharyngeal from other head and neck cancer and asymptomatic EBV-infections. Int J Cancer. 144:2555–2566. 2019. View Article : Google Scholar : PubMed/NCBI
19	Nakai W, Yoshida T, Diez D, Miyatake Y, Nishibu T, Imawaka N, Naruse K, Sadamura Y and Hanayama R: A novel affinity-based method for the isolation of highly purified extracellular vesicles. Sci Rep. 6:339352016. View Article : Google Scholar : PubMed/NCBI
20	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
21	Motokura T, Kobayashi Y, Fujita A, Nakamura Y, Taniguchi T, Uchimaru K and Asano S: Clinical significance of serial measurement of the serum levels of soluble interleukin-2 receptor and soluble CD8 in malignant lymphoma. Leuk Lymphoma. 16:355–362. 1995. View Article : Google Scholar : PubMed/NCBI
22	Jeppesen DK, Fenix AM, Franklin JL, Higginbotham JN, Zhang Q, Zimmerman LJ, Liebler DC, Ping J, Liu Q, Evans R, et al: Reassessment of exosome composition. Cell. 177:428–445. e182019. View Article : Google Scholar : PubMed/NCBI
23	Schneider RJ, Seibert K, Passe S, Little C, Gee T, Lee BJ III, Miké V and Young CW: Prognostic significance of serum lactate dehydrogenase in malignant lymphoma. Cancer. 46:149–143. 1980. View Article : Google Scholar
24	Geva M, Pryce A, Shouval R, Fein JA, Danylesko I, Shem-Tov N, Yerushalmi R, Shimoni A, Szydlo R, Pavlu J and Nagler A: High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma. Bone Marrow Transplamt. 56:2690–2696. 2021. View Article : Google Scholar : PubMed/NCBI
25	Tilly H, Castaigne S, Bordessoule D, Casassus P, Le Prisé PY, Tertian G, Desablens B, Henry-Amar M and Degos L: Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol. 8:272–279. 1990. View Article : Google Scholar : PubMed/NCBI
26	Carella AM, Podesta M, Frassoni F, Raffo MR, Pollicardo N, Pungolino E, Vimercati R, Sessarego M, Parodi C, Rabitti C, et al: Collection of ‘normal’ blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplant. 12:267–271. 1993.PubMed/NCBI
27	Du Bois D and Du Bois EF: A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 17:863–871. 1916. View Article : Google Scholar